|
1
|
Dudeck O and Ricke J: Advances in regional
chemotherapy of the liver. Expert Opin Drug Deliv. 8:1057–1069.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Oishi N and Wang XW: Novel therapeutic
strategies for targeting liver cancer stem cells. Int J Biol Sci.
7:517–535. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ma S, Chan KW, Lee TK, Tang KH, Wo JY,
Zheng BJ and Guan XY: Aldehyde dehydrogenase discriminates the
CD133 liver cancer stem cell populations. Mol Cancer Res.
6:1146–1153. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Huang X, Sheng Y and Guan M: Co-expression
of stem cell genes CD133 and CD44 in colorectal cancers with early
liver metastasis. Surg Oncol. 21:103–107. 2012. View Article : Google Scholar
|
|
6
|
Zhang H, Chang WJ, Li XY, Zhang N, Kong JJ
and Wang YF: Liver cancer stem cells are selectively enriched by
low-dose cisplatin. Braz J Med Biol Res. 47:478–482. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Faurobert E, Bouin AP and Albiges-Rizo C:
Microenvironment, tumor cell plasticity, and cancer. Curr Opin
Oncol. 27:64–70. 2015. View Article : Google Scholar
|
|
8
|
Ye J, Wu D, Wu P, Chen Z and Huang J: The
cancer stem cell niche: Cross talk between cancer stem cells and
their microenvironment. Tumour Biol. 35:3945–3951. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang BB, Cheng JY, Gao HH, Zhang Y, Chen
ZN and Bian H: Hepatic stellate cells in
inflammation-fibrosis-carcinoma axis. Anat Rec (Hoboken).
293:1492–1496. 2010. View
Article : Google Scholar
|
|
10
|
Friedman SL: Hepatic stellate cells:
Protean, multifunctional, and enigmatic cells of the liver. Physiol
Rev. 88:125–172. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Friedman SL, Sheppard D, Duffield JS and
Violette S: Therapy for fibrotic diseases: Nearing the starting
line. Sci Transl Med. 5:167sr12013.PubMed/NCBI
|
|
12
|
Coulouarn C, Corlu A, Glaise D, Guénon I,
Thorgeirsson SS and Clément B: Hepatocyte-stellate cell cross-talk
in the liver engenders a permissive inflammatory microenvironment
that drives progression in hepatocellular carcinoma. Cancer Res.
72:2533–2542. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jia CC, Wang TT, Liu W, Fu BS, Hua X, Wang
GY, Li TJ, Li X, Wu XY, Tai Y, et al: Cancer-associated fibroblasts
from hepatocellular carcinoma promote malignant cell proliferation
by HGF secretion. PLoS One. 8:e632432013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Han Z, Wang X, Ma L, Chen L, Xiao M, Huang
L, Cao Y, Bai J, Ma D, Zhou J, et al: Inhibition of STAT3 signaling
targets both tumor-initiating and differentiated cell populations
in prostate cancer. Oncotarget. 5:8416–8428. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bharadwaj U, Eckols TK, Kolosov M,
Kasembeli MM, Adam A, Torres D, Zhang X, Dobrolecki LE, Wei W,
Lewis MT, et al: Drug-repositioning screening identified
piperlongumine as a direct STAT3 inhibitor with potent activity
against breast cancer. Oncogene. 34:1341–1353. 2015. View Article : Google Scholar
|
|
16
|
Liu C, Zeng Y, Dai LH, Cai TY, Zhu YM, Dou
DQ, Ma LQ and Sun YX: Mogrol represents a novel leukemia
therapeutic, via ERK and STAT3 inhibition. Am J Cancer Res.
5:1308–1318. 2015.PubMed/NCBI
|
|
17
|
Stechishin OD, Luchman HA, Ruan Y, Blough
MD, Nguyen SA, Kelly JJ, Cairncross JG and Weiss S: On-target
JAK2/STAT3 inhibition slows disease progression in orthotopic
xenografts of human glioblastoma brain tumor stem cells. Neuro
Oncol. 15:198–207. 2013. View Article : Google Scholar :
|
|
18
|
Song L, Rawal B, Nemeth JA and Haura EB:
JAK1 activates STAT3 activity in non-small-cell lung cancer cells
and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling.
Mol Cancer Ther. 10:481–494. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Niu G, Wright KL, Ma Y, Wright GM, Huang
M, Irby R, Briggs J, Karras J, Cress WD, Pardoll D, et al: Role of
Stat3 in regulating p53 expression and function. Mol Cell Biol.
25:7432–7440. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wan S, Zhao E, Kryczek I, Vatan L,
Sadovskaya A, Ludema G, Simeone DM, Zou W and Welling TH:
Tumor-associated macrophages produce interleukin 6 and signal via
STAT3 to promote expansion of human hepatocellular carcinoma stem
cells. Gastroenterology. 147:1393–1404. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nieto N: Oxidative-stress and IL-6 mediate
the fibrogenic effects of [corrected] Kupffer cells on stellate
cells. Hepatology. 44:1487–1501. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Handy JA, Saxena NK, Fu P, Lin S, Mells
JE, Gupta NA and Anania FA: Adiponectin activation of AMPK disrupts
leptin-mediated hepatic fibrosis via suppressors of cytokine
signaling (SOCS-3). J Cell Biochem. 110:1195–1207. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Qi J, Xia G, Huang CR, Wang JX and Zhang
J: JSI-124 (Cucurbitacin I) inhibits tumor angiogenesis of human
breast cancer through reduction of STAT3 phosphorylation. Am J Chin
Med. 43:337–347. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Brechbuhl HM, Kachadourian R, Min E, Chan
D and Day BJ: Chrysin enhances doxorubicin-induced cytotoxicity in
human lung epithelial cancer cell lines: The role of glutathione.
Toxicol Appl Pharmacol. 258:1–9. 2012. View Article : Google Scholar :
|
|
25
|
Sun X, Huo X, Luo T, Li M, Yin Y and Jiang
Y: The anticancer flavonoid chrysin induces the unfolded protein
response in hepatoma cells. J Cell Mol Med. 15:2389–2398. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lirdprapamongkol K, Sakurai H, Abdelhamed
S, Yokoyama S, Athikomkulchai S, Viriyaroj A, Awale S, Ruchirawat
S, Svasti J and Saiki I: Chrysin overcomes TRAIL resistance of
cancer cells through Mcl-1 downregulation by inhibiting STAT3
phosphorylation. Int J Oncol. 43:329–337. 2013.PubMed/NCBI
|
|
27
|
Lin CM, Shyu KG, Wang BW, Chang H, Chen YH
and Chiu JH: Chrysin suppresses IL-6-induced angiogenesis via
downregulation of JAK1/STAT3 and VEGF: An in vitro and in ovo
approach. J Agric Food Chem. 58:7082–7087. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zheng X, Meng WD, Xu YY, Cao JG and Qing
FL: Synthesis and anticancer effect of chrysin derivatives. Bioorg
Med Chem Lett. 13:881–884. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ai XH, Zheng X, Tang XQ, Sun L, Zhang YQ,
Qin Y, Liu HQ, Xia H and Cao JG: Induction of apoptosis of human
gastric carcinoma SGC-7901 cell line by 5,
7-dihydroxy-8-nitrochrysin in vitro. World J Gastroenterol.
13:3824–3828. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ren KQ, Cao XZ, Liu ZH, Guo H, Quan MF,
Liu F, Jiang L, Xiang HL, Deng XY and Cao JG:
8-bromo-5-hydroxy-7-methoxychrysin targeting for inhibition of the
properties of liver cancer stem cells by modulation of Twist
signaling. Int J Oncol. 43:1719–1729. 2013.PubMed/NCBI
|
|
31
|
Quan MF, Xiao LH, Liu ZH, Guo H, Ren KQ,
Liu F, Cao JG and Deng XY: 8-bromo-7-methoxychrysin inhibits
properties of liver cancer stem cells via downregulation of
β-catenin. World J Gastroenterol. 19:7680–7695. 2013. View Article : Google Scholar
|
|
32
|
Ning Y, Li Q, Xiang H, Liu F and Cao J:
Apoptosis induced by 7-difluoromethoxyl-5,4′-di-n-octyl genistein
via the inactivation of FoxM1 in ovarian cancer cells. Oncol Rep.
27:1857–1864. 2012.PubMed/NCBI
|
|
33
|
Cao XZ, Xiang HL, Quan MF and He LH:
Inhibition of cell growth by BrMC through inactivation of Akt in
HER-2/neu-overexpressing breast cancer cells. Oncol Lett.
7:1632–1638. 2014.PubMed/NCBI
|
|
34
|
Lee KW, Yeo SY, Sung CO and Kim SH: Twist1
is a key regulator of cancer-associated fibroblasts. Cancer Res.
75:73–85. 2015. View Article : Google Scholar
|
|
35
|
Kalluri R and Zeisberg M: Fibroblasts in
cancer. Nat Rev Cancer. 6:392–401. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Pietras K and Ostman A: Hallmarks of
cancer: Interactions with the tumor stroma. Exp Cell Res.
316:1324–1331. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Xing F, Saidou J and Watabe K: Cancer
associated fibroblasts (CAFs) in tumor microenvironment. Front
Biosci (Landmark Ed). 15:166–179. 2010. View Article : Google Scholar
|
|
38
|
Yu H and Jove R: The STATs of cancer - new
molecular targets come of age. Nat Rev Cancer. 4:97–105. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yang XH, Zheng X, Cao JG, Xiang HL, Liu F
and Lv Y: 8-Bromo-7-methoxychrysin-induced apoptosis of
hepatocellular carcinoma cells involves ROS and JNK. World J
Gastroenterol. 16:3385–3393. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Xiao G, Tang X, Yao C and Wang C:
Potentiation of arsenic trioxide-induced apoptosis by
8-bromo-7-methoxychrysin in human leukemia cells involves depletion
of intracellular reduced glutathione. Acta Biochim Biophys Sin
(Shanghai). 43:712–721. 2011. View Article : Google Scholar
|
